Advertising

CVE:DOC

1.91
0.03 (1.55%)
CloudMD Software & Services is a rapidly growing technology company focused on digitizing the delivery of healthcare by providing patients access to all points of their care from their phone, tablet or desktop computer.
More at Wikipedia

Analysis and Opinions about DOC-X

Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
June 29, 2021
Telemedicine plus they use AI in their medical clinics. They make acquisitions to synergize and they grow organically. They boast $130 in revenue and $50 million in cash, so they can continue to buy more companies. It trades at 2.5x revenue vs.peers at 6x. Expect good multiple appreciation. Managers own a lot of stock and he's known them from the start. They execute well. They should rise a lot higher. (Analysts’ price target is $3.96)
Show full opinionHide full opinion
CloudMD (DOC-X)
June 29, 2021
Telemedicine plus they use AI in their medical clinics. They make acquisitions to synergize and they grow organically. They boast $130 in revenue and $50 million in cash, so they can continue to buy more companies. It trades at 2.5x revenue vs.peers at 6x. Expect good multiple appreciation. Managers own a lot of stock and he's known them from the start. They execute well. They should rise a lot higher. (Analysts’ price target is $3.96)
TOP PICK
TOP PICK
June 23, 2021
Healthcare solution providers. Acquisitions and organic growth. Really likes the recent push of one-stop healthcare shopping to employers and insurance companies. Sector has come down, waiting for two deals to close, trading at 3x profitable revenues. Great opportunity. No dividend. (Analysts’ price target is $3.96)
Show full opinionHide full opinion
CloudMD (DOC-X)
June 23, 2021
Healthcare solution providers. Acquisitions and organic growth. Really likes the recent push of one-stop healthcare shopping to employers and insurance companies. Sector has come down, waiting for two deals to close, trading at 3x profitable revenues. Great opportunity. No dividend. (Analysts’ price target is $3.96)
BUY
BUY
May 28, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It reported strong revenue growth at $8.8M. An increase of 187% YoY. They made 5 acquisitions and is well-capitalized to pursue more. There is also organic growth in all parts of the business. Long term outlook looks good. Unlock Premium - Try 5i Free

Show full opinionHide full opinion
CloudMD (DOC-X)
May 28, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It reported strong revenue growth at $8.8M. An increase of 187% YoY. They made 5 acquisitions and is well-capitalized to pursue more. There is also organic growth in all parts of the business. Long term outlook looks good. Unlock Premium - Try 5i Free

DON'T BUY
DON'T BUY
May 13, 2021
Loss of 2 cents this year, gain of 2 cents next year. Telemedicine is a fantastic opportunity, but not a lot of barriers to entry, and the big guys are already involved. He favours companies with high barriers to entry. PE of 100, so he'd pass.
Show full opinionHide full opinion
CloudMD (DOC-X)
May 13, 2021
Loss of 2 cents this year, gain of 2 cents next year. Telemedicine is a fantastic opportunity, but not a lot of barriers to entry, and the big guys are already involved. He favours companies with high barriers to entry. PE of 100, so he'd pass.
Robert McWhirter
Price
$1.870
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
March 25, 2021
(A Top Pick Apr 27/20, Up 282%) Tele-medicine. Expanded through Canada and now into US. Trading at lower valuation than peers. Just raised capital for more acquisitions of technology and clinics.
Show full opinionHide full opinion
CloudMD (DOC-X)
March 25, 2021
(A Top Pick Apr 27/20, Up 282%) Tele-medicine. Expanded through Canada and now into US. Trading at lower valuation than peers. Just raised capital for more acquisitions of technology and clinics.
BUY WEAKNESS
BUY WEAKNESS
January 25, 2021
They are doing a lot of interesting things. He decided to take a position in another in the space. The problem was the valuation. It is too expensive. It is a promising space in the long run. It is expensive right now but a well managed company. You need to buy it cheaply and smartly.
Show full opinionHide full opinion
CloudMD (DOC-X)
January 25, 2021
They are doing a lot of interesting things. He decided to take a position in another in the space. The problem was the valuation. It is too expensive. It is a promising space in the long run. It is expensive right now but a well managed company. You need to buy it cheaply and smartly.
BUY
BUY
December 8, 2020
It's in the hot telemedicine sector. This was a former top pick. Has done very well this year. They've built their platform this year. They've done a deal with pharmacies in the west, and have bought companies in tech and physical clinics. This will give their customers a choice between e-contacting a doctor and meeting one in person, or doing both. Vaccine needs is pressuring e-health stocks, but he expects this to continue growing.
Show full opinionHide full opinion
CloudMD (DOC-X)
December 8, 2020
It's in the hot telemedicine sector. This was a former top pick. Has done very well this year. They've built their platform this year. They've done a deal with pharmacies in the west, and have bought companies in tech and physical clinics. This will give their customers a choice between e-contacting a doctor and meeting one in person, or doing both. Vaccine needs is pressuring e-health stocks, but he expects this to continue growing.
BUY
BUY
September 1, 2020

WELL Health vs. Cloud MD, and buy the warrants? Different companies in the same sector. He owns both and expects both to excel in the coming year. Cloud MD just released earnings, not as strong as he expected, but talked about future catalysts coming in the fall. WELL just announced an acquisition and got financing from their biggest shareholder, Lee Ka-Shing. Both are equally good. Warrants: you could do this, but the challenge is that both stocks have enjoyed huge runs and profit-taking could happen. You have a finite time before those warrants expire worthless or you decide to exercise the warrants--it's riskier, though offers a higher return. In contrast, you can just hold onto the stock.

Show full opinionHide full opinion
CloudMD (DOC-X)
September 1, 2020

WELL Health vs. Cloud MD, and buy the warrants? Different companies in the same sector. He owns both and expects both to excel in the coming year. Cloud MD just released earnings, not as strong as he expected, but talked about future catalysts coming in the fall. WELL just announced an acquisition and got financing from their biggest shareholder, Lee Ka-Shing. Both are equally good. Warrants: you could do this, but the challenge is that both stocks have enjoyed huge runs and profit-taking could happen. You have a finite time before those warrants expire worthless or you decide to exercise the warrants--it's riskier, though offers a higher return. In contrast, you can just hold onto the stock.

BUY
BUY
July 2, 2020
They should be able to capitalize well on the COVID trend and then the telemedicine trend that will go on. CloudMD has an interesting platform. The stock has not done much in the last 6 weeks. They completed a financing. He suspects people were subscribing and then selling the stock and holding the warrant. He thinks it will continue to do well over the next two years.
Show full opinionHide full opinion
CloudMD (DOC-X)
July 2, 2020
They should be able to capitalize well on the COVID trend and then the telemedicine trend that will go on. CloudMD has an interesting platform. The stock has not done much in the last 6 weeks. They completed a financing. He suspects people were subscribing and then selling the stock and holding the warrant. He thinks it will continue to do well over the next two years.
Bruce Campbell (2)
Price
$0.000
Owned
Unknown
WATCH
WATCH
June 3, 2020
Tele-medicine? He likes this space. When they looked at what sectors will benefit post-pandemic, this was one. PM Trudeau has committed to putting government money into this space. What worries him about Canadian holdings, is that they are small fish in a big pond. Other companies already have over 50 million subscribers. Valuations are pretty stretched, so he would watch for good opportunities.
Show full opinionHide full opinion
CloudMD (DOC-X)
June 3, 2020
Tele-medicine? He likes this space. When they looked at what sectors will benefit post-pandemic, this was one. PM Trudeau has committed to putting government money into this space. What worries him about Canadian holdings, is that they are small fish in a big pond. Other companies already have over 50 million subscribers. Valuations are pretty stretched, so he would watch for good opportunities.
James Telfser
Price
$0.000
Owned
No
BUY
BUY
May 27, 2020
A past Top Pick. He likes them for their virtual health care service offerings during and after the pandemic. They just signed a deal to put kiosks in pharmacies. They had an equity offering that was 8 times over-subscribed.
Show full opinionHide full opinion
CloudMD (DOC-X)
May 27, 2020
A past Top Pick. He likes them for their virtual health care service offerings during and after the pandemic. They just signed a deal to put kiosks in pharmacies. They had an equity offering that was 8 times over-subscribed.
TOP PICK
TOP PICK
April 27, 2020

They can take advantage of COVID. They do telemedicine. They are just starting to get adoption.

Show full opinionHide full opinion
CloudMD (DOC-X)
April 27, 2020

They can take advantage of COVID. They do telemedicine. They are just starting to get adoption.

Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

CloudMD(DOC-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 7

Stockchase rating for CloudMD is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CloudMD(DOC-X) Frequently Asked Questions

What is CloudMD stock symbol?

CloudMD is a Canadian stock, trading under the symbol DOC-X on the TSX Venture Exchange (DOC-CV). It is usually referred to as TSXV:DOC or DOC-X

Is CloudMD a buy or a sell?

In the last year, 7 stock analysts published opinions about DOC-X. 6 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for CloudMD.

Is CloudMD a good investment or a top pick?

CloudMD was recommended as a Top Pick by Bruce Campbell (2) on 2021-06-29. Read the latest stock experts ratings for CloudMD.

Why is CloudMD stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CloudMD worth watching?

7 stock analysts on Stockchase covered CloudMD In the last year. It is a trending stock that is worth watching.

What is CloudMD stock price?

On 2021-07-23, CloudMD (DOC-X) stock closed at a price of $1.91.